A patient which has in comparison twice the VEGF-C concentration in serum, has a significant increased chance of response to bevacizumab by a factor of 2.79…logistic regression analysis adjusted with the aforementioned covariates revealed a significant association between VEGF-C levels and bevacizumab response (p = 0.034, Exp(B) = 2.79), indicating that in a patient with twice the VEGF-C concentration in serum, the chance of response to bevacizumab therapy increases by a factor of 2.79....our findings suggest that the VEGF-C serum level represent a novel biomarker that predicts response to bevacizumab maintenance treatment in primary ovarian cancer patients.